Compare PAYS & ARDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PAYS | ARDX |
|---|---|---|
| Founded | 2001 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 780.3M | 724.0M |
| IPO Year | 2020 | 2014 |
| Metric | PAYS | ARDX |
|---|---|---|
| Price | $9.40 | $3.11 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 11 |
| Target Price | ★ $14.81 | $12.50 |
| AVG Volume (30 Days) | 1.2M | ★ 4.6M |
| Earning Date | 11-09-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 85.71 | N/A |
| EPS | ★ 0.30 | N/A |
| Revenue | ★ $24,120,434.00 | $2,607,000.00 |
| Revenue This Year | $40.90 | $18.39 |
| Revenue Next Year | $12.70 | $26.08 |
| P/E Ratio | $31.48 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.08 | $2.80 |
| 52 Week High | $16.15 | $8.40 |
| Indicator | PAYS | ARDX |
|---|---|---|
| Relative Strength Index (RSI) | 26.49 | 48.00 |
| Support Level | $8.26 | $2.96 |
| Resistance Level | $14.06 | $3.38 |
| Average True Range (ATR) | 1.17 | 0.16 |
| MACD | -0.68 | 0.03 |
| Stochastic Oscillator | 3.13 | 49.18 |
PaySign Inc is a provider of prepaid card programs, comprehensive patient affordability offerings, digital banking services, and integrated payment processing designed for businesses, consumers, and government institutions. The company creates customized payment solutions for clients across industries, including pharmaceutical, healthcare, hospitality, and retail. The The company generates revenues from pharma card programs through card program management fees, transaction claim processing fees, interchange fees, customer service fees, other billable service fees and settlement income and other revenues are generated through cardholder fees, interchange fees, program management fees, load fees and breakage.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.